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ABSTRACT 
 
Background 
 
Older people are less likely to be included in clinical trials. Little is known about 
factors influencing older people’s decisions about participating in clinical trials. 
 
Objectives 
 
To examine the views of older people about participating in clinical trials. 
 
Methods 
 
Postal questionnaire to 801 participants who had completed the MAVIS nutrition 
trial, aged 65yrs and older. Closed and open questions sought participants’ views 
about factors important to them when deciding to take part in a trial, features of the 
MAVIS trial they liked and disliked and changes they would suggest. 
 
Results 
 
540 (59% of MAVIS trial participants) returned the questionnaire. The most 
important reasons reported for taking part in the trial were helping the research team 
and medical knowledge, and helping other older people. Participants valued good 
communication with the trial staff and good organisation. Participants reported 
concerns about swallowing pills and taking a placebo. Participants reported that 
future participation in trials could be influenced by poor health status.   
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Limitations 
 
This questionnaire surveyed older participants who had taken part in a randomised 
controlled trial. It did not elicit the views of people who had withdrawn or never 
decided to take part in the trial. 
 
Conclusions 
 
Older people report altruistic reasons for taking part in trials.  Simple trial designs, 
which minimise demands on participants and maintain good communications 
should be preferred. Explaining the need for older people, despite poor health, to 
participate in trials may help the generalisability of clinical trials. 
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BACKGROUND 
 
The randomised controlled trial (RCT) is widely accepted as the most powerful 
method to evaluate the effectiveness of new health technologies. However, low 
accrual and retention of participants can restrict the value of the trial, reducing the 
statistical power and generalisability [1,2]. A recent review reported that 31% of trials 
funded by the UK Medical Research Council and National Health Service Research 
and Development Health Technology Assessment Programme that recruited 
participants between 1994 and 2002 did not achieve their original recruitment target 
[3]. Older people, in particular, are less likely to be included in RCTs, restricting 
generalisability further [4].    
 
Studies which have examined factors influencing trial recruitment have often 
focussed on cancer trials [1,2,5,6] or hypothetical trials [7]. Trial recruitment is 
influenced by clinician and patient factors.  Clinician barriers identified [1,2,5] 
include time pressures and constraints, lack of staff and training, concern about the 
impact on the clinician-patient relationship, concern for the patients, loss of 
professional autonomy, and lack of reward and recognition. Barriers to participant 
accrual and factors influencing participation in RCTs include the extra demands of 
the study (e.g. additional procedures and appointments), patient treatment 
preferences and treatment uncertainty [1,2,5]. Factors affecting older people’s views 
on taking part in RCTs have seldom been examined. 
 
The aim of this study was to explore the factors that influence older people to take 
part and remain in randomised trials through surveying participants who had 
completed a randomised controlled trial investigating the effect of multimineral and 
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multivitamin supplements on infections, known as the Mineral And Vitamin 
Intervention Study (MAVIS trial) [8]. 
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METHODS 
 
The MAVIS trial design 
 
The MAVIS trial was a randomised, double blinded placebo-controlled trial which 
investigated the effect of a multimineral and multivitamin supplement on infections, 
health service use and quality of life in 910 community-dwelling people aged 65yrs 
and older in the Grampian region of Scotland. Full details of the trial are provided 
elsewhere [8]. Grampian Research Ethics Committee gave approval for the study. All 
older people covered by the general practices involved were eligible to take part, 
unless their general practitioners (GPs) had indicated that they were too unwell to be 
contacted, or they already took vitamin or mineral supplements.  Eligible older 
people were recruited by mailing them an initial invitation from their GP. Those who 
indicated they were interested returned a reply by post and were invited to an 
appointment in the GP’s surgery. 
 
Participants were asked to take one tablet a day for one year. They were also asked to 
record daily in a diary whether they had an infection and any contact with primary 
care for infection. At the end of each month participants returned the diary by post to 
the trial office, together with a questionnaire about trial tablet consumption over the 
last seven days. Ten percent of participants were also randomly selected to take part 
in a tablet count at six months and one year, requiring them to return unused tablets 
at these time points. Questionnaires for the Euroqol (EQ-5D) [9] and Short-Form-12 
(SF-12) [10] were completed at the GP visit and sent out at six months and one year.  
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Participants also completed digit span forwards [11] and verbal fluency [12] 
cognitive function tests at recruitment, and then by phone at one year. Two 
researchers were involved in recruitment (a research nurse and a research dietitian). 
Both researchers conducted the subsequent cognitive function tests by phone. 
Participants were also phoned shortly after recruitment to check that there were no 
concerns about the study. The two researchers or trial secretary also phoned 
participants if diaries or questionnaires were not returned after one postal reminder, 
or if there were queries about information provided in the diaries. 
 
After the end of the trial all participants who had not withdrawn or indicated they 
wished no follow-up were given details of their trial allocation and the results of the 
trial by post (801 of the 910 randomised). They were then sent this reply-paid follow-
up questionnaire by post, which contained closed and open questions about taking 
part in RCTs. No postal reminders were sent out for this questionnaire. 
 
Follow-up questionnaire 
 
The questions asked were informed by the findings from Prescott and colleague’s 
systematic review [1,2] and consultation with Professor Vikki Entwistle from the 
University of Dundee. Closed questions asked about motivating factors for taking 
part in a trial, health professional involvement, randomisation, use of a placebo, and 
filling in questionnaires. Quantitative methods were used to analyse participants’ 
responses to closed questions in the questionnaire. Categorical data were analysed 
using Chi-squared tests. Two-sided statistical significance was at the 5% level. For 
dichotomous variables odds ratios (ORs) are presented with 95% confidence 
intervals (CIs) for the proportion of participants responding to the closed questions 
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that were asked (active treatment vs blinded placebo). When comparing response 
rates for the proportions answering the closed questions between the treatment 
groups, non-responders were not included in the analysis. Participant data were 
stored, manipulated and analysed using SPSS version 11.5.1. 
 
The open questions focused on participants’ experience of the trial specifically asking 
“Would you consider taking part in a research study again, if asked?” We also looked at 
aspects that they liked by asking: “Are there things that you liked about the study?” 
Aspects that respondents disliked were also of interest, respondents were asked: “Are 
there things that you disliked about the study?” Respondents’ recommendations on how 
to improve the trial were also sought by asking: “Is there anything that you would have 
changed about the study?”  
 
Content analysis, a systematic method for assigning text to content categories [13] 
was used by PF to analyse the data given in response to open questions from the 
questionnaire. Responses from all open questions were read and reread, and the 
categories were generated through close inspection and comparison of the data. A 
second researcher (SM) assisted with analysing a sample of responses for each 
question to enhance the reliability and reproducibility of the coding. The coded data 
set was then entered into an Access database. The themes of the analysis are 
illustrated using representative quotations.  
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RESULTS 
 
Five hundred and forty (59%) of all 910 MAVIS trial participants returned the 
questionnaire.  Participants responding to the questionnaire did not differ by gender, 
type of residence or smoking status from all those randomised to the trial. However, 
they averaged one year younger than those recruited to the trial (data not shown). 
There was no statistically significant difference in proportions responding to the 
questionnaire between different arms of the trial [OR 1.12; 95% CI (0.83, 1.51); p = 
0.450] see Table 1.  
 
Closed questions  
 
There were no statistically significant differences in response rates to the closed 
questions between active and placebo arms of the trial, see Table 2. Overall, 86% of 
those responding to the survey reported that helping the research team was very 
important to them when deciding to take part in a study like MAVIS. Seventy-two 
percent of people rated helping other people like themselves as being an important 
issue when deciding to take part in a study like MAVIS.  
 
Under half of the people reported that being asked to take part by a doctor was very 
important to them. Whereas being asked by a nurse was rated to be less important 
when deciding to take part in a study. Thirty-four percent of respondents from the 
active treatment arm and 40% from the placebo arm reported that reducing their risk 
of illness was important to them when deciding to take part in a study. 
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Less important issues were knowing what was in the tablets, filling in a 
questionnaire or a diary. Least important issues were having to take tablets and 
having treatment decided by chance, particularly the possibility of having to take a 
placebo. 
 
Open Questions 
 
Written responses to the open questions are grouped into positive and negative 
aspects of the MAVIS trial, and factors impacting on people’s considerations about 
taking part in future research. 
 
Positive aspects of trial participation 
Trial communication and organisation  
 
Good communication and friendly personal contact between participants and trial 
staff seemed particularly important to people in the trial (n=88): 
 
 
 
 
 
 
 
Participants indicated that they liked the way in which the trial was organised and 
conducted by trial staff. In particular MAVIS trial participants made specific 
“I liked the friendly approach of those members of the team with which I came into contact with”. 
[Participant 011100.] 
 
“I liked the regular communication between researchers and subject.  This gave me a good feeling 
about the quality of the study.” [Participant 011012.] 
 
“You kept in touch and I felt part of the programme.” [Participant 011021.] 
 
“Over the period in question, I was treated with kindness and helped throughout.”  [Participant 
022009.] 
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reference to the value of face-to-face interviews, the design of the diaries, receiving 
Christmas cards and the general “friendliness” of those involved in the trial (n=52): 
 
 
 
 
 
 
Participants also reported that they had liked the simplicity and “straightforward” 
nature of their involvement (n=76):  
 
 
 
Negative aspects of trial participation 
 
Infection Diaries and questionnaires 
 
Although some people reported positive feelings towards completing their infection 
diary and completing questionnaires, this was the most frequently reported negative 
aspect of the trial (n=21). Some respondents suggested that instead of a daily diary 
they would have preferred a weekly diary: 
 
 
 
“The instructions were clearly understood.  The face-to-face interview with a member of the research 
team was excellent.  The layout of the diaries and the colour coding of the pages was also very good 
and easy to complete.” [Participant 011095.] 
 
“It was very well organised.” [Participant 052038.] 
 
“I thought it was very well organised.  The research nurses were very friendly and it was specially kind 
of them to send out cards to us at Christmas.” [Participant 032025.] 
“So easy and filling up the diary was no problem.” [Participant 011060.] 
 
“Very simple and straightforward, no complication.” [Participant 011130.] 
 
“It was very simple to take part.” [Participant 021008.] 
“I am not too keen on questionnaires but I know how important they are to research.” [Participant 
091025.] 
 
“Having to make a day-to-day diary and filling in forms and such like.” [Participant 011145.] 
 
“All the writing (which is done by my wife!).” [Participant 022055.] 
 
“I would have favored a weekly diary rather than a daily one.” [Participant 21048.] 
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Uncertainty of placebo and taking pills 
A number of people reported having concerns related to taking pills. Participants 
reported disliking having to swallow the pills as they found this difficult, or 
struggled to remember to take them each day (n=16):  
 
 
 
 
 
 
 
 
 
Some MAVIS participants reported having issues with the possibility of receiving a 
placebo, as they didn’t know what treatment they had been allocated to (n=12). A 
small number of people indicated that they would have preferred to receive the 
active treatment as opposed to the placebo. Only one participant from the active arm 
reported that they would have liked to know what the pill actually contained: 
 
 
 
 
 
 
“I would have excluded the placebo.” [Participant 091069.] 
 
“I would rather have known what type of tablet I was taking.” [Participant 011090.] 
 
“Not knowing if I was taking a vitamin or a dummy.” [Participant 011038.] 
 
“Wondering if it was placebo.” [Participant 011087.] 
 
“No - although a bit wary not knowing whether the tablet was a 'smarty' or the real thing.” [Participant 
012057.] 
 
“Being already on a lot of pills, my dislike was having to take more.” [Participant 012052.] 
 
“I'm not very good at swallowing capsules or tablets.” [Participant 022025.] 
 
“Having to remember to take the tablet each day.” [Participant 041057.] 
 
“I would prefer to see what results would be if I had taken minerals and vitamins.” [Participant 
091040.] 
 
“I would have preferred a share of the vitamin tablets as during the last 6 months, I thought the 
tablets contained vitamins so I was fooled.” [Participant 032010.] 
 
“Not really.  But it would have been interesting to know what the real tablets consisted of, especially 
as I was informed that I had been on the real tablets and not the placebos.” [Participant 092028.] 
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Duration of the trial 
On the whole MAVIS participants were positive about the one year duration of the 
trial. However, a small number of participants stated a dislike about the duration 
and commitment required of them during their participation of the trial (n=6). It was 
suggested that a study for a six-month period would have been preferable and more 
convenient to them. In terms of feedback of the trial results, a small number of 
participants (n=6) indicating that they would like to have known the trial outcome 
sooner. However, the length of time taken to conduct the trial may have been greater 
that expected by the participants due to the staggered recruitment: 
 
 
 
 
 
 
 
 
Taking part in future research 
 
It became clear, that when participants were asked if they would consider taking part 
in future research, their responses reflected their experiences of being a participant in 
the MAVIS trial. Participants reported both reasons for and against taking part in 
future research. In total, over half of the 540 MAVIS respondents indicated that they 
would be willing to take part in future research (n=283). 
 
 
“The length of time the survey carried on for and the commitment necessary to see it through.” 
[Participant 011090.] 
 
“Having wasted a year taking the placebo, I would have preferred if it had been 6 months vitamins 
and minerals and 6 months placebo, but still a blind test.” [Participant 31015.] 
 
“Perhaps the length of your study.  A six-month study might have been better.  Most volunteers went 
on holiday during the year and you feel having to take tablets while you were away was an 
inconvenience.  In my case I was in Australia.” [Participant 92077.] 
 
“Perhaps knowing the outcome a bit sooner - after a year you are inclined to forget if the vitamins 
made any difference to your health.” [Participant 042059.] 
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Altruism 
 
The most commonly described motivation by respondents for taking part in future 
research seemed to be based on a desire to “help” (n=181). Respondents described 
wanting to help other patients (n=92), and helping contribute towards furthering 
medical knowledge (n=76). The notion and desire to help by participating was a 
recurring theme throughout the data: 
 
 
 
 
 
 
Giving something back 
 
It was reported that participants’ decisions to take part in the MAVIS trial and trials 
in general included the consideration of being able to “giving something back” to the 
health service by taking part in the trial (n=18):  
 
 
 
 
 
 
 
 
“Yes, if it was going to help others.” [Participant 011129.] 
 
“Yes, because I like to think such research studies make meaningful contributions to medical 
knowledge and science.”  [Participant 011012.] 
 
“Yes, if the research will help elderly people in the future, then the study is worthwhile.” [Participant 
011006.] 
 
 
“Yes.  NHS has served me well over the years.  Taking part in studies is my way of saying thank 
you.” [Participant 11018.] 
 
“Yes, to put something back into the health service.” [Participant 11107.] 
 
“Yes, if the studies appear to be worthwhile.  A long time ago I did some research in a very different 
field and liked to be associated with research again even if the connection was very minor.” 
[Participant 011045.] 
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Weighing up future participation in trials 
 
Some people’s willingness to take part in future research appeared to depend on 
their expected involvement in the specific study, and any perceptions of personal 
benefit that might be gained through their participation: 
 
 
 
 
Of the 540 respondents around a fifth reported their unwillingness to participate in 
future studies (n=117). Additionally some participants’ considered how 
“worthwhile” a study would be when considering taking part in future research 
(n=15). The most frequently reported reason for not wishing to take part in future 
research was related to participants’ perceptions of age and poor health status which 
were perceived as potential barriers towards taking part in any future study (n=32): 
 
 
 
 
 
 
 
 
 
 
“Due to my age, I would not consider it practical for me to take part in any future research studies.” 
[Participant 011147.] 
 
“I think not.  There is a reluctance to take on commitments, which may not be completed or become 
an increasing burden at my time of life.  Resources of energy become increasingly depleted.”  
[Participant 011089.] 
 
“Just now I am having hospital tests.  So until I am finished I couldn't consider at the moment to take 
part in any study.” [Participant 011028.] 
 
“No.  I feel I have done my share.  This year I discovered I had CLL, which is being treated with 
tablets.  I have also had a hernia operation recently.” [Participant 022012.] 
“I might consider taking part, depending on what the research was.  The reason is that it would 
probably help others in the future.” [Participant 011081.] 
 
“Yes, but only if I felt comfortable about it and that would depend on what I had to do for the study.” 
[Participant 011002.]  
 17 
Personal interest in study and results 
 
Some participants reported their involvement in the trial as being “interesting” to 
them (n=17). Receiving feedback from the trial regarding the study’s findings was an 
aspect of the trial that some people reported liking (n=16). A number of participants 
also reported that trial participation gave them a “routine” which fitted into their 
lifestyle (n=15): 
 
 
 
 
 
 
 
“Yes.  I found it very friendly and most interesting.” [Participant 041084.] 
 
“I liked being kept in the picture of what was happening and the results.” [Participant 022096.]  
 
“It was easy to take part and did not interfere with my normal routine.” [Participant 011062.] 
 
“Taking tablet medication was a simple and easy thing to do, and there was no weighing of food 
included, so it was a simple routine to keep to.” [Participant 011024.] 
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DISCUSSION 
 
 
There are many barriers that prevent older people from taking part in randomised 
trials, restricting the value of trial findings. 
 
Designing trials with older people 
 
We found that the notion of “helping” is an important motivating factor in older 
people’s decisions about participation in RCTs. Ways in which participants reported 
helping included helping other patients and helping by contributing to medical 
knowledge. Other studies have found similarly altruistic reasons for people to take 
part in research [1,2,5,7,14-16]. Although, it is not clear whether older people 
demonstrate more altruism than younger people. 
 
Participants reported that their participation would “depend” on the demands of the 
trial, which will vary depending on the design of individual trials. Others have also 
identified that people’s decisions to participate depend on additional demands such 
as taking trial medication or additional travel and appointments [5,15]. It would be 
advisable to keep demands on participants to a minimum and make the trial as 
simple as possible, including providing transportation or covering its costs [17]. 
Some participants of the MAVIS trial referred to keeping the daily infection diaries 
and pills as being “easy” and “straightforward”. In particular, it is important to 
remember that this age group may already be taking several daily multiple dose 
medications in addition to any trial medication.   
 
 19 
Regular communication and the friendly approach used by the trial team was an 
aspect of the trial that participants valued, as was good organisation and the way in 
which the trial was conducted. Given the age and state of health of some participants 
communication may be particularly important as they may live alone and have 
limited contact with other people.  Similar social reasons for older people to take part 
in trials have also been found by Schron et al [18]. 
 
A small number of MAVIS participants felt that they would have preferred to receive 
the results sooner. As recruitment was staggered it took longer for those recruited at 
the start of the trial to receive feedback on the results than those recruited at the end 
of the trial. It would be advisable to discuss the duration of the trial and the time 
taken to receive feedback of the results to people at recruitment. 
  
Some participants had concerns regarding the placebo, which have been reported in 
other studies [1,2,5,15,19,20]. It is particularly important to have adequate time to 
clearly explain the reasons for randomisation and a placebo, concepts which are 
difficult for participants of all ages to grasp and recall [5-7,16,21].  
 
Planning trials with older people involves considerations specifically for this age 
group, and potential participants should be involved in the study design process [7]. 
Some people felt that their health and age would not allow them to take part in a trial 
or that they might not be of use to the trial as they were too old. Ill health and 
depression in this age group are particularly important reasons for discontinuing a 
trial once enrolled [22]. Explaining the need for older people, despite poor health, to 
participate in trials may help the generalisability of clinical trials. Trial staff need to 
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be sensitive to these issues, as well as avoiding prejudicial terms such as ‘geriatric’, 
which may discourage older people from participating [23].  
 
Limitations 
 
The results of this study must be interpreted within the context of the MAVIS trial – 
participants completed the questions having already taken part in the trial and had 
received the trial results. We did not seek responses from people refusing to 
participate in the trial which would have given a broader perspective.   
 
The questionnaire was not piloted with older people prior to administration, as it 
was not feasible due to the very short timescale of the funding. However, the 
questions asked were provided by researchers who had already undertaken research 
on patient participation in trials. Piloting the questionnaire may have identified 
potential issues which could have been addressed [24].  
 
The questions were asked in the order of closed questions first, followed by open 
questions. The closed questions may have prompted participants’ responses to the 
open questions that followed. However, using both closed and open questions in that 
order is useful for topics about which little is known [25]. 
 
Analysis of data from open questions was primarily conducted by one researcher, 
which may potentially introduce researcher bias.  To help reduce such biases a 
second researcher (SM) independently checked a sample of responses for each 
question.  
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The nature of the trial and those involved may have affected the results and 
generalisability of the findings. The trial investigated the effect of multimineral and 
multivitamin supplementation on infections (particularly common infections like 
upper respiratory tract infections), which may be viewed as less severe conditions 
than cancer or heart disease. The multimineral and multivitamin supplement may 
have caused less concern about possible side-effects - an important issue for older 
people [21,23,26]. Thus participants’ responses may be less relevant to participants 
recruited to trials related to life-threatening illnesses. Most MAVIS trial participants 
were under 85yrs of age, so findings may not be generalisable to the oldest old. 
 
Conclusions 
Older people have often been excluded from clinical trials as a direct consequence of 
exclusion criteria focussing on pre-existing illnesses and medication use, rather than 
age per se [6].  With the need to ensure that older people are represented in clinical 
trials, we need to ensure that concerns of older people are properly addressed.   
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* OR 1.12; 95% CI (0.83, 1.51); p = 0.450
Table 1: Flow chart of MAVIS trial participants 
  
Active treatment arm N (%) Placebo arm N (%) 
   
Total N randomised 456 454 
N sent questionnaire  402 (88) 399 (88) 
    
  
N responding to questionnaire  266 (58) 274 (60)* 
    
Age - mean [SD] 72 [5] 72 [5] 
Aged ≥85 5 (2) 8 (3) 
Sex female  132 (50) 125 (46) 
Sex male  134 (50) 149 (54) 
Current smoker  32 (12) 26 (10) 
Lives in the community  259 (97) 271 (99) 
Lives in a nursing home  7 (3) 3 (1) 
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Table 2: Which of these are important to you when deciding to take part in a study like MAVIS? 
  
Active treatment arm N=266 Placebo arm N=274 p-value 
Not at all n (%) A little n (%) A lot n (%) Not at all n (%) A little n (%) A lot n (%) 
        
a. The research will help other people like me 6 (2) 56 (21) 191 (72) 7 (2) 62 (23) 197 (72) 0.928 
b. The research will help the research team 3 (1) 27 (10) 227 (85) 1 (1) 30 (11) 236 (86) 0.565 
c. Taking part may reduce my risk of illness 38 (14) 121 (45) 89 (34) 52 (19) 102 (37) 109 (40) 0.068 
d. Being asked by a doctor to take part 61 (23) 70 (26) 112 (42) 67 (25) 77 (28) 117 (43) 0.960 
e. Knowing what is in the tablets 112 (42) 69 (26) 71 (26) 115 (42) 75 (27) 70 (26) 0.918 
f. Having the possibility of taking a dummy tablet (a 
placebo tablet) 164 (62) 63 (24) 24 (9) 159 (58) 65 (24) 36 (13) 0.309 
g. Being asked by a nurse to take part 83 (31) 88 (33) 73 (28) 85 (31) 94 (34) 79 (29) 0.967 
h. Having to take tablets 130 (49) 66 (25) 54 (20) 141 (52) 67 (24) 57 (21) 0.952 
I. Having my treatment decided by chance 114 (43) 82 (31) 52 (19) 115 (42) 81 (30) 62 (23) 0.708 
j. Having to fill in questionnaires or diaries 109 (41) 75 (28) 66 (25) 114 (42) 83 (30) 66 (24) 0.91 
  
Percentages may not calculate to 100% as not all people completed the questions. 
  
 
 
